Iovance Biotherapeutics Inc (IOVA)

[GMH*]

I generally do not rely on analyst price targets. I have a biotech that I have had for years (probably too long) where the price targets have been consistently low of 1/2 of current price and high of 2x and the average is the current stock price. I bought it at $12 and it currently sits at $41.

I have found that analysts often send their juniors to the Q&A calls (listen for so and so sitting in for the lead analyst comments) in the smaller biotech space. I also do not know how often they update models. We still have at least one analyst with Q2 revenues below $6M. The 20 starts already reported will exceed that.